The University of Manchester has ambitious plans to develop ground-breaking research in neuro-oncology.
To achieve this ambition of delivering the best patient care through cutting-edge research, neuro-oncology is an area of strategic priority. By bringing together neurosurgeons, clinicians, and scientists from the University and various partner organisations across Greater Manchester, the ambition is to establish a leading centre for research into brain tumours.
The appointment of a Chair in Neuro-oncology is the first step in realising this ambition with the successful candidate being expected to take on an exciting leadership role, attract significant research income, and to produce high quality outputs with academic and socio-economic impact
Find out more about the role and to apply here
As well as developing collaborations with researchers in the Division of Neuroscience and Experimental Psychology, where there is significant expertise in neuroimmunology and neuroimaging, the successful candidate will also work closely with the Manchester Cancer Research Centre (MCRC). MCRC is a strong partnership between The Cancer Domain within the University of Manchester, The Christie NHS Foundation Trust and Cancer Research UK.
This partnership has since been expanded to include research activity at Manchester University NHS Foundation Trust (MFT) and the Manchester Centre for Clinical Neurosciences (MCCN) at Salford Royal NHS Foundation Trust.
The MCCN hosts the Greater Manchester Neuro-Oncology and Skull Base Multi-Discplinary Teams (MDT) which cumulatively discuss approximately 4,000 brain tumour cases annually. From these more than 500 patients undergo surgery creating the highest throughput of brain and central nervous system (CNS) tumours in the UK and one of the biggest in Europe.
The Royal Manchester Children’s Hospital (RMCH) is the largest single-site children’s hospital in the UK and one of the largest in Europe.
As a pioneering centre with internationally famed clinical expertise, a heritage of applied research, and a catchment population of over one million children, RMCH is well placed to lead global firsts in treatments for paediatric cancer.
In partnership with the Christie Hospital, RMCH is the lead UK site for paediatric proton beam radiotherapy support and is one of only two UK sites to incorporate a stem, CAR-T and gene cell therapy clinical unit.
RMCH also works as part of the North West Paediatric Neurosciences Operational Delivery Network, primarily with our partner organisation, Alder Hey Children’s Hospital in Liverpool.
This new role aims to actively build research capacity in neuro-oncology to maintain a high international reputation based on research, innovation and impact.
Contact information for enquiries: Professor Stuart Allan, Professor of Neuroscience, [email protected]